The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
The players are vying in the CD19 x CD20 Car-T arena.
But the former is paying a fraction of what Merck shelled out for raludotatug.
The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.
INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.
Casdatifan might have found its sweet spot, as part of a Cabometyx combo.
Ibtrozi breezes through FDA review and gives Nuvation its first approval.